Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for IDEAYA Biosciences (IDYA) over the last 7 years, with Q3 2025 value amounting to $12.2 million.

  • IDEAYA Biosciences' Share-based Compensation rose 3257.73% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.8 million, marking a year-over-year increase of 4573.67%. This contributed to the annual value of $34.7 million for FY2024, which is 8792.8% up from last year.
  • As of Q3 2025, IDEAYA Biosciences' Share-based Compensation stood at $12.2 million, which was up 3257.73% from $11.9 million recorded in Q2 2025.
  • In the past 5 years, IDEAYA Biosciences' Share-based Compensation registered a high of $12.2 million during Q3 2025, and its lowest value of $1.9 million during Q1 2021.
  • Moreover, its 5-year median value for Share-based Compensation was $4.7 million (2023), whereas its average is $5.7 million.
  • In the last 5 years, IDEAYA Biosciences' Share-based Compensation skyrocketed by 15303.43% in 2021 and then soared by 2192.32% in 2025.
  • Quarter analysis of 5 years shows IDEAYA Biosciences' Share-based Compensation stood at $2.1 million in 2021, then skyrocketed by 44.14% to $3.0 million in 2022, then skyrocketed by 61.28% to $4.8 million in 2023, then soared by 97.69% to $9.5 million in 2024, then increased by 28.8% to $12.2 million in 2025.
  • Its last three reported values are $12.2 million in Q3 2025, $11.9 million for Q2 2025, and $10.2 million during Q1 2025.